SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is a San Diego, California-based biotech company developing treatments for cancer, intractable pain, and COVID-19. The company has eight manufacturing sites, five in the US and three in China. ADVERTISEMENT In a research note issued to investors on November 2, Brandon Folkes at Cantor Fitzgerald started coverage on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) with a target price of $5 and assigned the stock an Overweight rating. The target price reflects a handsome upside potential of 284% from the closing price as of December 7. In August, the drug candidate SP-103 from Scilex, Sorrento Therapeutics, Inc.'s (NASDAQ:SRNE) majority-owned subsidiary, was given fast-track status by the U.S. Food and Drug Administration (FDA). The drug is targeted toward the treatment of severe low back pain (LBP). Folkes believes that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has the ability to develop multiple best-in-class products in high-value fields of oncology, non-opioid pain relief, and infectious diseases like COVID-19. Experts think Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is trading at a significant valuation discount compared to its rivals, making it one of the best small-cap stocks to invest in.
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | SORRENTO THERAPEUTICS Hauptdiskussion | ||
| 2 | SORRENTO INFORMATIV | ||
| 3 | Sorrento, Spam frei!! | ||
| 4 | Ausschließlich Sorrento News | ||
| 5 | Never Surrender ✌️ |
|
|
Thema | ||
|---|---|---|---|
| 1 | MicroStrategy | +9,97 % | |
| 2 | NVIDIA Hauptdiskussion | -0,81 % | |
| 3 | für alle, die es ehrlich meinen beim Traden. | ||
| 4 | Dax Prognose | +0,05 % | |
| 5 | Canopy Hauptforum | +0,76 % | |
| 6 | BAYER Hauptdiskussion | -2,31 % | |
| 7 | PAG911 | -3,64 % | |
| 8 | BTC/USD Hauptdiskussion | +3,10 % | |
| 9 | TARGET Hauptdiskussion | -18,27 % | |
| 10 | GAMESTOP Hauptdiskussion | +1,22 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | MicroStrategy | +10,06 % | |
| 2 | NVIDIA Hauptdiskussion | -0,84 % | |
| 3 | Canopy Hauptforum | +0,76 % | |
| 4 | BAYER Hauptdiskussion | -2,61 % | |
| 5 | PAG911 | -3,66 % | |
| 6 | TARGET Hauptdiskussion | -18,46 % | |
| 7 | Nio für normale Kommunikation | -4,81 % | |
| 8 | GAMESTOP Hauptdiskussion | +1,31 % | |
| 9 | NEL ASA Hauptdiskussion | -8,14 % | |
| 10 | Marathon Digital Holdings | +7,90 % | Alle Diskussionen |